U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21ClO4
Molecular Weight 360.832
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOFIBRATE

SMILES

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl

InChI

InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

HIDE SMILES / InChI

Molecular Formula C20H21ClO4
Molecular Weight 360.832
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25903954

Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. It’s used as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII (an inhibitor of lipoprotein lipase activity), which increases lipolysis and elimination of triglyceride-rich particles from plasma. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Fenofibrate also has an off-label use as uricosuric therapy in people who have gout.

CNS Activity

Curator's Comment:: fenofbrate cannot cross the blood-brain barrier and reach the central nervous system

Originator

Curator's Comment:: Procetofen was synthesized in 1974 and was introduced in clinical practice in France the same year. Procetofen, which significantly decreased plasma lipid concentrations in hyperlipidemic patients, was later called fenofibrate to comply with World Health Organization nomenclature guidelines

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

1.09952644E12
Palliative
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

1.09952644E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.96 μg/mL
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.9 μg × h/mL
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.1 h
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16 h
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Other AEs: Asthenia, Pain...
Other AEs:
Asthenia (1.1%)
Pain (1.1%)
Headache (3.4%)
Migraine (2.3%)
Dyspepsia (2.3%)
Gastrointestinal disorder (1.1%)
Nausea (3.4%)
Diarrhoea (1.1%)
Myalgia (1.1%)
Dizziness (1.1%)
Abnormal thinking (1.1%)
Sources:
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Other AEs: Abdominal pain, Back pain...
Other AEs:
Abdominal pain (4.6%)
Back pain (3.4%)
Headache (3.2%)
Nausea (2.3%)
Constipation (2.1%)
Abnormal liver function tests (7.5%)
ALT increased (3%)
CPK increased (3%)
AST increased (3.4%)
Respiratory disorder (6.2%)
Rhinitis (2.3%)
Urticaria (1.1%)
Rash (1.4%)
Sources:
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
unhealthy
n = 46
Health Status: unhealthy
Condition: hyperlipoproteinaemia
Sex: M+F
Population Size: 46
Sources:
AEs

AEs

AESignificanceDosePopulation
Abnormal thinking 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Asthenia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Diarrhoea 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Dizziness 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Gastrointestinal disorder 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Myalgia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Pain 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Dyspepsia 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Migraine 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Headache 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Nausea 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 49.5
n = 87
Health Status: unhealthy
Condition: dyslipidemia
Age Group: 49.5
Sex: M+F
Population Size: 87
Sources:
Urticaria 1.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Rash 1.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Constipation 2.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Nausea 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Rhinitis 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
ALT increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
CPK increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Headache 3.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
AST increased 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Back pain 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Abdominal pain 4.6%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Respiratory disorder 6.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Abnormal liver function tests 7.5%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
unhealthy, adult
n = 439
Health Status: unhealthy
Condition: dyslipidemia
Age Group: adult
Population Size: 439
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
weak
weak
yes [IC50 170 uM]
yes [IC50 2.39 uM]
yes [IC50 5.83 uM]
yes [Inhibition 50 uM]
yes [Ki 105.2 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.
2001 Apr
LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy.
2001 Apr
Fenofibrate raises plasma homocysteine levels in the fasted and fed states.
2001 Apr
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
2001 Dec
Rare side-effects of fenofibrate.
2001 Feb
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.
2001 Feb
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
2001 Feb 1
Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography.
2001 Jan
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
2001 Jan 1
Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates.
2001 Jan 15
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
2001 Jan 16
Effect of fenofibrate on fatty liver in rats treated with alcohol.
2001 Jun
Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
2001 Mar
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
2001 May 15
Fibrates and homocysteine.
2001 Nov-Dec
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].
2001 Oct
Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
2001 Oct
[Pleiotrophic effect of anti-hyperlipemic agents].
2001 Oct 10
Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene.
2001 Oct 5
Cerivastatin and gemfibrozil-associated rhabdomyolysis.
2001 Sep
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.
2001 Sep
[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
2002 Feb
Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.
2002 Mar
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
2002 Mar
Patents

Sample Use Guides

Primary Hypercholesterolemia or Mixed Hyperlipidemia: the initial dose of TRICOR (FENOFIBRATE TABLETS) is 145 mg per day Hypertriglyceridemia: the initial dose is 48 to 145 mg per day
Route of Administration: Oral
Fenofibrate may protect against endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiachypertrophy and heart failure.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:59:45 UTC 2021
Edited
by admin
on Fri Jun 25 20:59:45 UTC 2021
Record UNII
U202363UOS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOFIBRATE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FENOFIBRATE [WHO-DD]
Common Name English
FENOFIBRATE [MI]
Common Name English
FENOFIBRATE [USP]
Common Name English
ANTARA
Brand Name English
FENOFIBRATE [USAN]
Common Name English
FENOFIBRATE [EP MONOGRAPH]
Common Name English
LIPOFEN
Brand Name English
LIPANTIL
Brand Name English
FENOFIBRATE DELAYED RELEASE
Common Name English
TRIGLIDE
Brand Name English
FENOFIBRATE [USP MONOGRAPH]
Common Name English
FENOGLIDE
Brand Name English
FENOFIBRATE [VANDF]
Common Name English
FENOFIBRATE [MART.]
Common Name English
FENOFIBRATE [JAN]
Common Name English
FENOFIBRATE MICRONIZED
Common Name English
FENOFIBRATE [EMA EPAR]
Common Name English
FENOFIBRATE [USP-RS]
Common Name English
ISOPROPYL 2-(P-(P-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPIONATE
Common Name English
LIPIDIL
Brand Name English
TRICOR
Brand Name English
FENOFIBRATE [HSDB]
Common Name English
FENOFIBRATE [ORANGE BOOK]
Common Name English
FENOFIBRATE [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175375
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-VATC QC10BA03
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-ATC C10BA04
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
LIVERTOX 403
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
NCI_THESAURUS C98150
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-VATC QC10AB05
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-ATC C10BA03
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-ATC C10AB05
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
WHO-VATC QC10BA04
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
NDF-RT N0000170118
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
NDF-RT N0000175596
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
NDF-RT N0000170118
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
Code System Code Type Description
INN
3996
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
EVMPD
SUB07576MIG
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
IUPHAR
7186
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
HSDB
7736
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
NCI_THESAURUS
C29047
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
CAS
49562-28-9
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
ChEMBL
CHEMBL672
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
RXCUI
221100
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
DRUG BANK
DB01039
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
FDA UNII
U202363UOS
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
ECHA (EC/EINECS)
256-376-3
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
LACTMED
Fenofibrate
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
MESH
D011345
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
DRUG CENTRAL
1152
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
RXCUI
8703
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
ALTERNATIVE
WIKIPEDIA
FENOFIBRATE
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
MERCK INDEX
M5279
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY Merck Index
EPA CompTox
49562-28-9
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
PUBCHEM
3339
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY
USP_CATALOG
1269447
Created by admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
PRIMARY USP-RS
Related Record Type Details
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC